Navigation Links
Cellular Biomedicine Group Announces Adjournment of Its Annual Shareholder Meeting
Date:11/9/2013

PALO ALTO, Calif., Nov. 9, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG) today convened the annual meeting of its shareholders. Because a quorum was not achieved by shares present at the meeting in person or by proxy, the shareholder meeting was adjourned to a later date as to be determined by the board of directors of the Company. The board of directors has fixed the close of business on November 18, 2013 as the record date for the determination of stockholders entitled to notice of and to vote at the annual meeting. New proxy materials will be distributed to all the shareholders. Management of the Company is confident that a quorum will be achieved in the re-convened meeting.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contact:

Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566 5064
sarah.kelly@CellBioMedGroup.com


'/>"/>
SOURCE Cellular Biomedicine Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Dynamics Announces Commercial Launch of iCell® Neurons for Neuroscience Drug Discovery
2. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
3. Proteins shine a brighter light on cellular processes
4. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
5. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
6. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
7. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
8. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
9. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
10. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
11. Cellular Therapy and Cord Blood 2013 Market Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... up human tissue regeneration from small lab samples to full-size tissues, bones, even ... to establish a vascular system that delivers blood deep into the developing tissue. ...
(Date:3/22/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused on ... today that Dr. Miriam Kidron , Oramed,s ... "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," ... Peptide Therapeutics (OPT) Boston Conference in Cambridge, ...
(Date:3/22/2017)... TORONTO , March 22, 2017 /PRNewswire/ - ... Therapeutics (the "Company" or "Propellon"), a start-up created ... WDR5-targeted anti-cancer therapeutics. FACIT,s investment, combined with non-dilutive ... lead program. The seed funding enables Propellon to ... position the Company for financing and/or entering a ...
(Date:3/22/2017)... ... 2017 , ... Okyanos Cell Therapy has announced Tallahassee, FL will be the ... “Stem Cell Therapy: The Next Phase in the Evolution of Medicine.” As the Bahamas’ ... and Therapy Act, Okyanos maintains a mission to help “no-option” patients and those ...
Breaking Biology Technology:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
(Date:2/22/2017)... , Feb. 22, 2017 With the ... ABI Research identifies four technologies that innovative and ... secure significant share in the changing competitive landscape: ... passive authentication.   "Companies can no ... to security," says Dimitrios Pavlakis , Industry ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):